EXEL
$EXEL
Exelixis, Inc.
Oncology-focused biotech company with Cabometyx for kidney and liver cancers.
Healthcare$43.68
-0.78 (-1.75%)
Day Range$43.50 - $44.30
Prev Close$44.46
Analyst Rating
Buy
15 Buy / 10 Hold / 1 Sell
Subscribers
0
Tracking this ticker
Next Report
—
Weekly updates
Latest Report
EXEL: Exelixis — Value Play with Kidney Cancer Upside
Exelixis ($EXEL) looks like a fundamentally healthy biotech with high profitability, low leverage and exposure to a growing kidney cancer market. Catalysts include pipeline progress and upcoming Q1 results on May 11, 2026.
Apr 6, 2026